Feasibility of Semaglutide in Advanced Lung Disease
Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease
About this trial
This is an interventional treatment trial for Obesity focused on measuring semaglutide
Eligibility Criteria
Inclusion Criteria: Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension Age > 18 BMI > 30 kg/m2 Requires supplemental oxygen on exertion Stable treatment regimen X 90 days Use of disease-modifying therapy Exclusion Criteria: Diabetes Pregnant or Breastfeeding Recent weight loss Recent or chronic GI complaints History of gastroparesis History of scleroderma Hospitalized at time of evaluation Use of weight loss medication in last 90 days Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2) Uncontrolled thyroid disease History of acute/chronic pancreatitis Prior suicide attempt Suicidal ideation in last 90 days Presence of a pacemaker or defibrillator
Sites / Locations
Arms of the Study
Arm 1
Experimental
Study Drug (semaglutide)
Semaglutide Pen Injector 1.0 mg weekly Once weekly subcutaneous injection Other Name: Wegovy